Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
News|Articles|August 2, 2022
- Pharmaceutical Technology, August 2022
- Volume 46
- Issue 8
- Pages: 35–41
Thermogelling Matrix-Containing Platelet Lysate-Loaded Elastic Liposomes as a Potential Treatment of Wounds
The purpose of this article was to demonstrate the application of a new thermogelling matrix in the healing of wounds.
Advertisement
This work focuses on the preparation, characterization, and evaluation of a thermogelling matrix of Pluronic F-127 containing elastic liposomes loaded with a platelet lysate and which is intended for healing wounds. In this study, elastic liposomes were characterized, and their biological activity was confirmed. Liposomes were obtained that had a high encapsulation rate. The formulation of liposomes in a thermogelling matrix based on Pluronic F-127 improved the properties of the product, favoring its application and retention on the skin, and promoting tissue regeneration, both on a culture of fibroblasts, and in vivo in mice. The results showed that this system is a potentially good alternative for the treatment of wounds based on its ability to protect the platelet lysate, allow its gradual release, produce a semi-occlusive effect on the skin, and promote fast tissue regeneration.
Peer-reviewed research
Submitted: Feb. 21, 2022
Accepted: June 9, 2022
About the authors
Sergio A. Bernal-Chávez, PhD, is research associate, and Adriana Ganem-Rondero*, PhD,
*To whom all correspondence should be addressed.
Article details
Pharmaceutical Technology
Vol. 46, No. 8
August 2022
Pages: 35–41
Citation
When referring to this article, please cite it as S.A. Bernal-Chávez, et al., “Thermogelling Matrix-Containing Platelet Lysate-Loaded Elastic Liposomes as a Potential Treatment of Wounds,” Pharmaceutical Technology 46 (8) 35–41 (2022).
Articles in this issue
about 4 years ago
What Goes Wrong When API Quality is Compromised?about 4 years ago
Mitigating the Risk from Excipient Variabilityabout 4 years ago
Adapting to Solubility/Bioavailability Challengesabout 4 years ago
Progress in the Development of CAR NK-Cell Therapiesabout 4 years ago
Vaccine Administration: The Growing Role of Prefilled Syringesabout 4 years ago
Inspecting Finished Products with Precisionabout 4 years ago
An Integrated Approach to the Data Lifecycle in BioPharmaabout 4 years ago
Detecting Apparent Total Nitrosamine Content in Pharmaceutical Drugsabout 4 years ago
Automating Packaging of Bio/PharmaceuticalsAdvertisement
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Advertisement
Advertisement